Regarding the treatment of chronic hepatitis B, many treatment guidelines have been issued in various regions and countries around the world, the most famous of which are from the American (AASLD), European (EASLD), and Asia-Pacific (APASLD) guidelines for the treatment of liver disease, and these guidelines, as well as mainland China’s own guidelines for the treatment of chronic hepatitis B, describe the ultimate goal of treating chronic hepatitis B as. ” maximum long-term suppression or clearance of the hepatitis B virus to reduce hepatocyte inflammation, necrosis, and liver fibrosis, with the aim of delaying and stopping the progression of hepatitis B to serious complications such as cirrhosis and liver cancer”. This paragraph can easily lead to the misunderstanding that the ultimate goal of treating chronic hepatitis B is to maximize long-term suppression or clearance of the hepatitis B virus, so some hepatitis B virus carriers approach their doctors and say, “Doctor, my hepatitis B virus is very high, please hurry up and get it under control with medication!” In fact, hepatitis B carriers are not suitable for antiviral treatment. The above paragraph should be interpreted in this way: the real ultimate goal of our treatment for chronic hepatitis B is the latter sentence: “to delay and stop the progression of hepatitis B to serious complications such as cirrhosis and liver cancer”, and “to suppress or eliminate the hepatitis B virus to the maximum extent possible” is only the means we adopt to achieve this goal. The “maximum suppression or elimination of the hepatitis B virus” is only the means and measures we take to achieve this goal. Anti-viral treatment can “reduce inflammation, necrosis and liver fibrosis of hepatocytes” and ultimately achieve the goal of “delaying and stopping the progression of hepatitis B to serious complications such as cirrhosis and liver cancer”.